Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
2022; Baishideng Publishing Group; Volume: 13; Issue: 6 Linguagem: Inglês
10.5306/wjco.v13.i6.448
ISSN2218-4333
AutoresKathrine S Rallis, Dimitrios Makrakis, Ioannis A. Ziogas, Georgios Tsoulfas,
Tópico(s)Immunotherapy and Immune Responses
ResumoHepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in chronically inflamed livers. Advanced HCC is managed with systemic therapies; the tyrosine kinase inhibitor (TKI) sorafenib has been used in 1
Referência(s)